| Masala S, 2011[@527622] |
Both |
Mild radiculopathy after RFA treatment (n=1) |
N/A |
| Roberto L cazzato, 2020[@527623] |
Both |
RFA: Post operative pain (n=1), Brachial plexus syndrome (n=1).
CA: Heal hypoesthesia (n=1), Partial S1 motor deficit (n=1), Gluteal anesthesia and bladder disfunction (n=1). |
N/A |
| Pierre de marini, 2020[@527616] |
Both |
RFA: Septic shock due to an infection of the RFA site (n=1). CA: Fracture(n=4), Tumor seeding (n=1), Infection(n=1) , Arterial bleeding (n=1), Hypotension(n=1) |
N/A |
| LUIGI ZUGARO, 2016[@527624] |
Both |
Transient nerve injuries (RFA n= 1) (CA n= 1) |
CA: 12% of patients experienced recurrence.
RFA: 8% of patients experienced recurrence. |
| Paul G. Thacker, 2011[@527614] |
Both |
RFA: Minimal damage to liver capsule (n=1).
CA: Temporary S1 vertebra dysesthesia (n=1), Thermal injury (n=1) |
N/A |
| Taylor J. Greenwood, 2015[@527634] |
RFA |
Post-procedural radicular pain (n=1) |
At 3 months, 12 out of 13 patients had stable treated disease, and all 10 patients assessed at 6 months maintained stability. |
| Longpo Zheng, 2014[@527635] |
RFA |
No major adverse events were reported |
The mean follow-up duration was 8.4 ± 2.1 months, with no recurrence reported during this period. |
| Athour Gevargez, 2007[@527625] |
RFA |
Pain and numbness in their contralateral lower limbs (n=2), Unilateral monoradiculopathy (n=1), Paresthesia (n=1) |
Mean time to progression: 730 ± 54 days; 28/33 patients free of tumor progression, while 5 patients showed local tumor progression. |
| Roberto L Cazzato, 2018[@527636] |
RFA |
PMMA leakage into para-vertebral soft tissues (n=1),
Sepsis and death in end stage lung cancer patient (n=1) |
Imaging follow-up in 6/11 (54.5%) patients, Local disease was stable in 4 cases and Progression in 2 cases |
| Wei Zhao, 2018[@527637] |
RFA |
Cement leakage and pain (n=1) |
Patients are followed up after 12 months of ablation, with no reported cases of tumor recurrence |
| Dawood Sayed, 2019[@527638] |
RFA |
No major adverse events were reported |
N/A |
| Sandeep Bagla, 2016[@527639] |
RFA |
Pain outside the target vertebrae (n = 3), Ruptured disk
(n = 1), Neuropathic pain (n = 1), Syncope (n = 1) |
N/A |
| Sherry, 2020[@527641] |
RFA |
Neuritis (n=4), Numberness (n=-2), Dysesthesia (n=1) |
N/A |
| Noboru Tanigawa, 2018[@527640] |
RFA |
Pain (n=1), Hypotension (n=1), First degree burn (n=1), Death due to progression of hepatocellular carcinoma (n=1) |
N/A |
| BelfioreG, 2008[@527630] |
RFA |
No major adverse events were reported |
N/A |
| Matthew P. Goetz, 2004[@527628] |
RFA |
Second degree burn (n=1), Transient bowel and bladder incontinence (n=1), Fracture of acetabulum (n=1) |
N/A |
| Matthew R, 2002[@527629] |
RFA |
Second degree burn (n=1) |
N/A |
| Jack W. Jennings, 2021[@527642] |
CA |
Fourth-degree burn and amputation (n=1), Abdominal pain (n=1), Hematoma (n=1), Other mild side effects (n=14) |
N/A |
| Fenqiang Li, 2014[@527643] |
CA |
Fever (n=15), Muscle pain (n=3), Hypercalcemia (n=2), Pathological fracture (n=5) |
N/A |
| Matthew R. Callstrom, 2013[@527633] |
CA |
Osteomyelitis (n=1) |
N/A |
| Salvatore Masala, 2010[@527644] |
CA |
Post-procedure pain (n=7) |
N/A |
| Matthew R. Callstrom, 2006[@527645] |
CA |
No major adverse events were reported |
N/A |
| Francesco Arrigoni, 2022[@527627] |
CA |
Bleeding at the site of cryoablation (n=1) |
Local Tumor Control Outcomes in Follow-up Period (Mean: 22.4): 10/11 (91%) showed no progression. |
| Yumei Yang, 2020[@527626] |
CA |
Fracture (n =1), Skin frostbite (n =1), Sciatic nerve compression (n =1) |
N/A |
| Nicolas Gallusser, 2019[@527610] |
CA |
Pathologic fracture (n=1) |
6/16 (37%) had local disease progression.
Mean time to progression: 5.9 months |
| TatumA.McArthur, 2017[@527646] |
CA |
Neuropraxia (n=1) |
Follow-up Period (Mean: 436 days):
1/16 (6.2%) showed disease progression at ablation site |
| Alessandro Motta, 2017[@527647] |
CA |
Transient post-operative unilateral lower extremity radiculopathy and weakness (n=2) |
N/A |
| Adam N. Wallace, 2016[@527632] |
CA |
Hemothorax (n=2) ,Transient foot drop (n=1) |
The overall radiographic local tumor control rate at 3 months: 90% (37/41), at 6 months was 86% (32 of 37) and at 12 months: 79% (26/33). Local progression was documented in 12% of cases within 1 year |
| A.Tomasian, 2016[@527631] |
CA |
Unilateral lower extremity radiculopathy and weakness (n=2) |
Follow-up Period: Median 10 months.
Local Tumor Control Rates: 30/31 (96.7%) achieved complete local tumor control. |
| Ryan M.Hegg, 2014[@527648] |
CA |
Soft tissue infection (n=1) |
Primary Tumor Control: 60% (3/5 patients).
After Repeat Cryoablation: 80% (4/5 patients). With a median follow-up of 8.4 months |